Pre DiabetesMG4NCT07886372
Effects of Mango on Insulin Sensitivity in Prediabetes
A study testing Mango juice in people with Pre Diabetes, run by Clinical Nutrition Research Center, Illinois Institute of Technology at 1 site in United States.
Trial summary
The purpose of this study is to determine whether daily mango consumption for 6 weeks can improve glucose utilization in individuals with prediabetes. The findings from this research may help explore the potential role of mangoes in a healthy diet for people at risk of developing type 2 diabetes Read more about this study
- Who is it for?
- Ages 25 to 60 years
- Conditions the study is for
- Pre Diabetes
- What is being tested?
- Mango juice
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 64 participants
- Where
- 1 siteUnited States
- Study dates
- 28 Oct 2026to 29 Dec 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Be between 25-60 years old.
- Have a BMI of 25-35 kilograms per square meter.
- Have fasting blood glucose between 100-125 milligrams per deciliter or Glycated hemoglobin (HbA1c) between 5.7-6.4%.
- Be non-smokers for at least 12 months.
- Be generally healthy, with no major organ-related diseases.
- Not take medications or supplements that could interfere with the study.
- Be able to follow study procedures, including dietary restrictions and scheduled visits.
Who cannot join
- Smoke, vape, or use marijuana.
- Have allergies or intolerance to mangoes or study foods.
- Have blood pressure above 160/100 millimeters of Mercury.
- Have fasting blood glucose above 125 milligrams per deciliter.
- Have a history of major heart disease, stroke, or cancer in the past five years.
- Be pregnant, planning to become pregnant, or breastfeeding.
Show all 16Show fewer
- Take anti-inflammatory drugs or certain dietary supplements.
- Have had major surgery or trauma in the past two months.
- Follow extreme diets (e.g., vegan, Atkins).
- Have used antibiotics in the last six weeks.
- Have a history of eating disorders or substance abuse in the past two years.
- Drink more than three cups of coffee or tea per day.
- Have donated blood in the last three months.
- Be professional athletes or do excessive exercise.
- Have had weight changes of more than 11 pounds in the past two months.
- Work overnight shifts.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Clinical Nutrition Research Center
Chicago, Illinois, 60616
Indika Edirisinghe, PhD, 708-563-8178, iedirisi@illinoistech.edu
Chelsea Preiss, M.S., 708-563-1576, cpreiss@illinoistech.edu
About this study
Official title: Investigating the Effects of Mango Consumption on Whole-body Insulin Sensitivity and the Potential Mechanisms Involved in Individuals With Pre-diabetes.
The purpose of this study is to determine whether daily mango consumption for 6 weeks can improve glucose utilization in individuals with prediabetes. The findings from this research may help explore the potential role of mangoes in a healthy diet for people at risk of developing type 2 diabetes
Read the detailed description
The proposed project is based on the hypothesis that mango enhances whole-body insulin sensitivity through increased antioxidant-mediated mechanisms. Accordingly, the primary objective is to explore whole-body insulin sensitivity, as measured by the Matsuda index, in individuals with Pre-DM following 6 weeks of mango consumption. The secondary objective is to clarify the underlying mechanism of action through enhanced antioxidant status. The tertiary object will be to monitor glucose concentration using CGM before and during (the last 10 days of the interventions) to understand the real-time dynamic glucose changes with the mango interventions compared to the control intervention.
This study will last for about six weeks and involves a total of six visits to our Clinical Nutrition Research Center at Illinois Tech (CNRC). These visits include one screening visit to see if you are eligible to participate in this study, followed by Visits 1, 2, 3, 4, and 5. During the study, participant will be asked to drink a mango drink or a simple controlled drink every day for 42 days. Also, they will wear a small device called a continuous glucose monitor (CGM) for a period of 7 days at two different times in the study. This device remains on their skin and tracks their blood sugar level day and night, so we can see how it changes in real time.
Screening Visit:
Participant's eligibility for the study is based on the inclusion and exclusion criteria listed above. To assess this, they will need to arrive at the CNRC fasting for 10-12 hours, meaning no food or drink other than plain water during this period.
During the screening visit, the following assessments will be conducted:
- The participant will complete a screening questionnaire about their health, dietary habits, and physical activity history.
- The participant's height, weight, waist circumference, and body composition will be measured. Their Body Mass Index (BMI) will be calculated based on their height and weight. BMI is an estimate of body fat that applies to both adult men and women.
- The participant's forehead temperature, blood pressure, and heart rate will be measured. They will be seated in a comfortable chair with their feet flat on the ground and uncrossed. They will be asked to relax for five minutes before their blood pressure and heart rate are recorded.
- A finger prick test will be performed to check their blood sugar levels.
- A licensed healthcare practitioner (LHCP) and/or a certified phlebotomist will assess their arm veins using a vein access scale test. A butterfly needle will then be used to draw 3 milliliters (mL) of blood from their arm to measure their plasma blood glucose levels.
- If the participant is a woman under the age of 60 year, they will be required to take a pregnancy test.
Also participants will complete a Food Frequency Log to evaluate their typical consumption patterns for specified food products. For each listed food item, participants will report their intake frequency by selecting one of five response options: more than once per day, once per day, 2-3 times per week, once per week, or not at all.
Based on the results of the questionnaire, blood glucose levels, physical measurements, and overall health evaluation, the participant may meet the eligibility criteria and be invited to participate in the study.
Procedures for Each Study Day Visit (Visits 1, 2, 3, 4 and 5):
VISIT 1: (which may take place on the same day as the screening visit or on a different day)
If participant qualify based on your screening results, visit 1 can take place immediately after your screening or on a later date. This visit lasts approximately 30-45 minutes, during which participant will meet with one of our investigators who will provide detailed instructions on the study procedures and how to prepare for each study day. Participant will also receive training on study procedures, including dietary restrictions, medications, and supplements to avoid, food and GI-tract diary recording, and overnight fasting requirements. Study dates will be scheduled, and participant will receive a study booklet containing the study calendar and all the instructions covered during visit 1.
CGM Placement: During this visit, the study staff will prepare the participant for glucose monitoring. A Continuous Glucose Monitor (CGM) will be placed on participant's arm. This is a small sensor that remains on skin to monitor the blood glucose levels.
Diet restrictions ("Foods to Avoid"): Participant will be asked to continue their usual dietary habits throughout study. However, certain foods and beverages must be avoided, as they may interfere with our ability to assess the effects of mango consumption.
They will be asked to limit their intake of mango, dark chocolate, chestnut, cloves and red wine throughout the study. Additionally, participants will be provided a specific list of foods to avoid for three days prior to each longer study visit (Visits 2 and 5), along with a separate 24-hour avoidance list before those visits.
ASA24 Food Recall: To help track diet, participant will use an online tool called the ASA24 to report all food and beverages consumed during the previous day. They will complete this questionnaire during every single study visit, including Visits 1, 2, 3, 4, and 5. In addition to these visits, they will complete the ASA24 weekly at home to document what they ate the day before. Each questionnaire takes about 45 minutes to finish. To make this easier, they will get regular reminders, so they know exactly when to complete their weekly records.
GI-tract Diary: To help us understand gut, participant will simply answer a few questions about your stomach and digestion by ticking the boxes that best describe how you feel.
Visit 2 and 5: LMTT (Liquid Meal Test)
Participant will be asked to fast for at least 10 hours (no food or drink except plain water). We will collect their initial fasting blood. They will be asked to consume a liquid meal consisting of two bottles of Ensure Original Nutrition Shake. This meal provides 440 kcal, 20 g of sugar, 12 g of fat, and 10 g of protein. To see how their body processes the meal, additional blood samples will be and collected at specific times: one fasting blood draw before the LMTT followed by 15mins, 30mins, 60mins, 90mins, 120mins, 180mins and 240mins after they finish the drink.
At the end of Visit 2, they will be given a 16-day supply of study beverages to take home and consume daily until their next visit.
Before each of the study day visit:
The day before your Study Day Visit, they will review the instructions on "How to Prepare for Your Study Day". This will include guidelines for eating a standardized dinner meal, fasting overnight for at least 10 hours (which aligns with typical overnight fasting). They will also be asked to avoid vigorous physical activity and alcoholic beverages for the 24 hours preceding their study day, aim for their usual night's sleep, and maintain their normal diet except for the specified restrictions under "Foods and Beverages to AVOID or Limit."
3-Day food record: Three days before their Study Days, they will avoid mango, dark chocolate, red wine, almonds, walnuts and pecans. Additionally, they must refrain from consuming caffeinated beverages and alcohol for 24 hours before the Study Day. During this period, they will complete a three-day consecutive food record, documenting everything they eat and drink, including the portion size, from the time they wake up until they go to sleep.
Standardized Meal: The night before Visit 2 and 5, they will eat a repeatable dinner of either a homemade meal or a frozen meal provided to you by CNRC, similar as Visit 1.
ASA24 and GI-tract diary: During your visits, you will use the online links to fill out your ASA24 food record and answer the GI-Track questionnaire about their gut health.
At the end of the Study Days: They will be evaluated for safety and any discomfort or symptoms before leaving and will be given a 16-days supply of study beverages to take home and consume daily until their next visit. They will receive a take-home snack, and compensation will be issued after all study procedures are completed. Additionally, they will be given instructions on how to prepare for their next visit.
How much blood will be collected during the study visit? Blood will be collected a total of eight times on each visit (Visits 2 and 5), for approximately 91 mL of blood collected per visit. Throughout the entire study, a total of approximately 190 mL of blood will be collected.
Visit 3: Pickup Day This is a shorter visit designed to keep the participant supplied for the study. Staff will briefly meet with them to see how they are doing. They will pick up their next 19-days supply of study beverages to last until Visit 4.
ASA24 and GI-tract diary: During visit, they will use the online links to fill out their ASA24 food record and answer the GI-Track questionnaire about gut health.
Visit 4: Pickup visit and Second CGM Placement A new Continuous Glucose Monitor (CGM) sensor will be placed on participant's arm to monitor their glucose levels leading up to their final visit. They will pick up their next 7-days supply of study beverages to last until Visit 5.
ASA24 and GI-tract diary: During their visit, they will use the online links to fill out your ASA24 food record and answer the GI-Track questionnaire about their gut health.
- Conditions
- Pre Diabetes
- Being tested
- Mango juice, Control Beverage
- Medical subject headings
- Glucose Intolerance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mango juiceOther
Mango beverage
Control BeverageOther
Italian Ice beverage
| Study group | Role | What they receive |
|---|---|---|
| Mango beverage | Experimental | 1 cup (165 grams) of mango smoothie twice a day. Receives: Other: Mango juice |
| Control (no mango) | Placebo comparator | calorie-matched control intervention Receives: Other: Control Beverage |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fasting Plasma Glucose Concentration
Fasting plasma glucose concentration will be measured in plasma samples using a Randox automated clinical analyzer.
Measured: Baseline and Week 6
Fasting Plasma Insulin Concentration
Fasting plasma insulin concentration will be measured in plasma samples using a Randox automated clinical analyzer.
Measured: Baseline and Week 6
Insulin Sensitivity
The Matsuda index for insulin sensitivity will be calculated using validated equations based on paired glucose and insulin values obtained during the Liquid Meal Tolerance Test (LMTT).
Measured: Baseline and Week 6
Secondary outcomes (5)
Plasma Glutathione Peroxidase Activity
Plasma glutathione peroxidase activity will be measured to assess systemic antioxidant enzyme activity before and after the intervention.
Measured: Baseline and Week 6
Plasma Superoxide Dismutase Activity
Plasma superoxide dismutase activity will be measured to assess systemic antioxidant enzyme activity before and after the intervention.
Measured: Baseline and Week 6
Expression of Nrf-2 Pathway Genes
Relative expression of target genes (Nrf-2, glutathione peroxidase 2 [GLx2], glutathione S-transferase [GST], and NAD(P)H:quinone oxidoreductase-1 [NQO1]) will be quantified from blood collected in Paxgene tubes using qPCR.
Measured: Baseline and Week 6
Continuous Glucose Monitoring (CGM)
Interstitial glucose profiles will be captured using a continuous glucose monitor worn for 7-days before the LMTT.
Measured: 7-day monitoring periods at baseline and Week 6
Fasting Plasma Triglyceride Concentration
Fasting plasma triglyceride concentration will be measured in plasma samples using a Randox automated clinical analyzer.
Measured: Baseline and Week 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Oct 2026
- Study start28 Oct 2026 (estimated)
- Primary completion30 Sep 2027 (estimated)
- Study completion29 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pre DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The proposed study is a randomized, 2-arm, parallel design lasting approximately 6 weeks.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 64 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- National Mango Board
- Responsible party
- Sponsor
- Investigators
- Britt Burton-Freeman, PhD, Principal investigator, Illinois Institute of TechnologyAmandeep Sandhu, PhD, Principal investigator, Illinois Institute of Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07886372
- Sponsor's protocol ID
- IRB-2026-47
- Acronym
- MG4
- Status last verified
- Oct 2026
- First submitted
- 7 Oct 2026
- Last updated
- 21 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No